Home LiteratureArticle Details
PMID: 6345130 Published · ppublish English Journal Article Review

Protein binding displacement interactions and their clinical importance.

Drugs ·Vol. 25 ·No. 5 ·1983-05-00 ·Pages 495-513

McElnay JC, D'Arcy PF

Abstract

The binding of drugs to proteins is an important pharmacokinetic parameter. Many methods are available for the study of drug protein binding phenomena and there are also many ways to interpret the binding data. Although much emphasis has been placed on the binding of drugs in the plasma, binding also takes place in the tissues. Displacement interactions involving plasma or tissue binding sites have been implicated as the causative mechanisms in many drug interactions. However, the importance of plasma binding displacement as a mechanism of drug interactions. However, the importance of plasma binding displacement as a mechanism of drug interaction has been overestimated and overstated, being based largely on in vitro data. Because displaced drug can normally distribute out of the plasma compartment, increases of free drug concentrations are usually transient and therefore will not give rise to changed pharmacological effects in the patient. Those clinically important drug interactions formerly considered to be caused via displacement from plasma binding sites usually have another interaction mechanism involved; commonly decreased metabolism or renal elimination also takes place. Plasma binding displacement interactions, however, do become important clinically in certain specific situations, namely, when the displacing drug is administered quickly to the patient by the intravenous route, during therapeutic drug monitoring, and in certain drug disposition studies which involve the use of a heparin lock for blood sampling. Tissue binding displacement interactions have a greater potential to cause adverse effects in the patient as in this case drug will be forced from extravascular sites back into the plasma. The resulting increased drug plasma levels will lead to enhanced pharmacological effects and, possibly, frank toxicity. Displacement of drugs from binding sites simultaneously in both the plasma and in the tissues will combine the effects seen after displacement from the separate areas. Due to decreased binding in both areas, the free drug concentration in the plasma will increase leading to overactivity of the displaced drug.

MeSH Terms
Animals Binding Sites/drug effects Binding, Competitive Blood Proteins/metabolism Drug Interactions Humans Kinetics Pharmaceutical Preparations/metabolism Protein Binding
Chemicals
Blood Proteins Pharmaceutical Preparations
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
McElnay J C
D'Arcy P F
References (91)
91 references, click to expand
  1. Disopyramide.
    N Engl J Med. 1979 Apr 26;300(17):957-62 PMID: 431563
  2. Tissue binding of drugs.
    J Pharm Sci. 1977 Aug;66(8):1211-2 PMID: 894516
  3. Serum protein binding of diphenylhydantoin in man. II. Interaction with sodium valproate in epileptic patients.
    Farmaco Prat. 1979 Jan;34(1):46-8 PMID: 378689
  4. Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids.
    Clin Pharmacol Ther. 1970 Jul-Aug;11(4):524-9 PMID: 5429179
  5. Effect of heparin administration on plasma binding of benzodiazepines.
    Br J Clin Pharmacol. 1980 Feb;9(2):171-5 PMID: 6101958
  6. An in vitro model of drug-albumin interaction [proceedings].
    J Pharm Pharmacol. 1977 Dec;29 Suppl:1P PMID: 22637
  7. The influence of acetylsalicyclic acid on the binding of acetrizoate to human albumin.
    Ann N Y Acad Sci. 1973 Nov 26;226:341-54 PMID: 4520401
  8. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.
    N Engl J Med. 1971 Jul 29;285(5):264-7 PMID: 4378402
  9. Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.
    Br Med J (Clin Res Ed). 1982 Jan 2;284(6308):13-6 PMID: 6797618
  10. Phenytoin-salicylate interaction.
    Clin Pharmacol Ther. 1981 Jan;29(1):56-60 PMID: 7460475
  11. Quinidine-digoxin interaction.
    N Engl J Med. 1980 Jan 17;302(3):176 PMID: 7350450
  12. Influence of sulfaethidole on the human pharmacokinetics of dicloxacillin.
    J Clin Pharmacol. 1980 Aug-Sep;20(8-9):534-42 PMID: 6893599
  13. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects.
    Clin Pharmacol Ther. 1980 Dec;28(6):779-89 PMID: 6777108
  14. The binding of drugs by plasma proteins.
    J Pharm Sci. 1968 Jun;57(6):895-918 PMID: 4876452
  15. Interaction between azapropazone and warfarin.
    Br Med J. 1977 May 7;1(6070):1193-4 PMID: 861532
  16. Interaction of several coumarin compounds with human and canine plasma albumin.
    Mol Pharmacol. 1971 Mar;7(2):209-18 PMID: 5125855
  17. Binding of drugs to human serum albumin. XIV. The theoretical basis for the interaction between phenytoin and valproate.
    Mol Pharmacol. 1980 Sep;18(2):237-42 PMID: 6775182
  18. The displacement of phenylbutazone-14C and warfarin-14C from human albumin by various drugs and fatty acids.
    Biochem Pharmacol. 1968 Jan;17(1):143-51 PMID: 5638549
  19. Binding of a new antitumor agent, thalicarpine, to DNA.
    J Pharm Sci. 1974 Mar;63(3):474-5 PMID: 4856551
  20. The displacing effect of a fatty acid on the binding of diazepam to human serum albumin.
    Biochem Pharmacol. 1975 Jul 15;24(13-14):1361-2 PMID: 1148025
  21. Prednisone side-effects and serum-protein levels. A collaborative study.
    Lancet. 1971 Oct 9;2(7728):778-80 PMID: 4106604
  22. Potentiation of anticoagulant effect of warfarin by phenylbutazone.
    N Engl J Med. 1967 Mar 2;276(9):496-501 PMID: 6018280
  23. Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects.
    Clin Pharmacol Ther. 1980 Feb;27(2):170-8 PMID: 7353335
  24. The effect of azapropazone on the binding of warfarin to human serum proteins [proceedings].
    J Pharm Pharmacol. 1978 Dec;30 Suppl:73P PMID: 32332
  25. Myocardial distribution of digoxin and renal function.
    Clin Pharmacol Ther. 1974 Sep;16(3):449-54 PMID: 4414761
  26. Optical studies on the mechanism of the interaction of the enantiomers of the antiocagulant drugs phenprocoumon and warfarin with human serum albumin.
    Mol Pharmacol. 1977 Jan;13(1):70-9 PMID: 834186
  27. Valproic acid: in vitro plasma protein binding and interaction with phenytoin.
    Ther Drug Monit. 1979;1(1):105-16 PMID: 121944
  28. Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate.
    N Engl J Med. 1970 Oct 15;283(16):827-31 PMID: 5458032
  29. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.
    N Engl J Med. 1980 Jan 3;302(1):33-5 PMID: 7350395
  30. Valproic acid-phenytoin interaction.
    Ther Drug Monit. 1979;1(2):243-8 PMID: 122160
  31. Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites.
    Pharmacol Ther. 1982;17(2):211-20 PMID: 6757977
  32. Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling.
    Clin Pharmacol Ther. 1979 Jan;25(1):103-7 PMID: 758239
  33. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.
    Epilepsia. 1973 Jun;14(2):177-84 PMID: 4515987
  34. Bilirubin binding to hepatic Y and Z protein (ligandin): tissue bilirubin concentrations in phenobarbital treated Gunn rats (38466).
    Proc Soc Exp Biol Med. 1975 Jan;148(1):9-13 PMID: 1168914
  35. Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin.
    Clin Pharmacol Ther. 1979 Jan;25(1):61-6 PMID: 758244
  36. Salivary levels of anticonvulsants: a practical approach to drug monitoring.
    Neurology. 1977 May;27(5):409-13 PMID: 16232
  37. A rapid method for the determination of salicylate binding by the use of ultrafilters.
    J Pharm Pharmacol. 1972 Oct;24(10):786-9 PMID: 4403975
  38. Valproic acid dosage and plasma protein binding and clearance.
    Clin Pharmacol Ther. 1980 Oct;28(4):486-92 PMID: 6773716
  39. Problems associated with analysis and interpretation of small molecule/macromolecule binding data.
    J Pharm Pharmacol. 1978 Feb;30(2):69-74 PMID: 24106
  40. Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients.
    Eur J Clin Pharmacol. 1981;21(3):235-42 PMID: 7032949
  41. Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.
    Clin Pharmacol Ther. 1970 Nov-Dec;11(6):846-55 PMID: 4394754
  42. Effect of ibuprofen on protein binding of warfarin in human serum.
    J Pharm Sci. 1977 Jul;66(7):1060 PMID: 886450
  43. Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs.
    Ann N Y Acad Sci. 1971 Jul 6;179:213-25 PMID: 5285376
  44. A previously unrecognized drug interaction between quinidine and digoxin.
    Clin Cardiol. 1979 Feb;2(1):40-2 PMID: 498605
  45. Lignocaine disposition in blood in epilepsy.
    Br J Clin Pharmacol. 1981 Nov;12(5):663-6 PMID: 7332731
  46. Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion.
    Br J Clin Pharmacol. 1982 Feb;13(2):245-9 PMID: 6800390
  47. Drug-protein binding: recent advances in methodology: spectroscopic techniques.
    Ann N Y Acad Sci. 1973 Nov 26;226:44-59 PMID: 4129140
  48. Competitive binding between cocaine and various drugs to synthetic levodopa melanin.
    J Pharm Sci. 1977 Nov;66(11):1544-7 PMID: 915728
  49. Monitoring prednisone and prednisolone.
    Ther Drug Monit. 1980;2(2):169-76 PMID: 6762710
  50. Albumin metabolism.
    Gastroenterology. 1973 Feb;64(2):324-37 PMID: 4568596
  51. Phenylbutazone: plasma concentrations and effectiveness in patients with rheumatoid arthritis.
    J Int Med Res. 1977;5 Suppl 2:40-7 PMID: 913873
  52. Interaction between azapropazone and warfarin.
    Experientia. 1978 Oct 15;34(10):1320-1 PMID: 738406
  53. Propranolol binding in plasma during cardiopulmonary bypass.
    Anesthesiology. 1979 Dec;51(6):512-6 PMID: 517778
  54. Letter: Effect of plasma protein binding on elimination of warfarin.
    J Pharm Sci. 1974 May;63(5):805-6 PMID: 4830012
  55. Drug-protein binding: recent advances in methodology: nuclear magnetic resonance.
    Ann N Y Acad Sci. 1973 Nov 26;226:60-8 PMID: 4588444
  56. Direct and indirect determination of binding constants of drug-protein complexes with microparticles.
    J Pharm Sci. 1978 Jan;67(1):107-9 PMID: 619095
  57. Cooperativity of warfarin binding with human serum albumin induced by free fatty acid anion.
    Biochem Pharmacol. 1978 Mar 1;27(5):739-43 PMID: 656112
  58. Intravenous valproate: effects on plasma and saliva phenytoin levels.
    Neurology. 1981 Apr;31(4):467-70 PMID: 6783979
  59. Spuriously high values of unbound drug fraction in serum as determined by the new ultrafree anticonvulsant drug filters.
    Br J Clin Pharmacol. 1981 Nov;12(5):753-6 PMID: 7332742
  60. On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.
    Br J Clin Pharmacol. 1982 Mar;13(3):411-5 PMID: 7059443
  61. Blood collection techniques, heparin and quinidine protein binding.
    Clin Pharmacol Ther. 1979 Feb;25(2):204-10 PMID: 759074
  62. Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications.
    N Engl J Med. 1979 Aug 23;301(8):400-4 PMID: 460341
  63. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease.
    Clin Pharmacol Ther. 1974 Mar;15(3):276-82 PMID: 4815953
  64. The distribution and concentration of tritiated digoxin in human tissues.
    Ann Intern Med. 1967 Jan;66(1):116-24 PMID: 6015582
  65. Pharmacokinetics of indomethacin.
    Clin Pharmacol Ther. 1975 Sep;18(3):364-73 PMID: 1100305
  66. Failure of indomethacin and warfarin to interact in normal human volunteers.
    J Clin Pharmacol. 1975 Jul;15(7):486-95 PMID: 1150903
  67. Displacement of albumin-bound warfarin by anti-inflammatory agents in vitro.
    J Pharm Pharmacol. 1980 Oct;32(10):709-11 PMID: 6107346
  68. An in vitro study of drug displacement interactions: warfarin-salicylate and warfarin-phenylbutazone.
    J Pharm Pharmacol. 1979 May;31(5):322-30 PMID: 37303
  69. Plasma protein binding and therapeutic drug monitoring.
    Ther Drug Monit. 1980;2(1):29-37 PMID: 6762701
  70. Interpretation of protein-drug interaction through fraction bound and relative contribution of secondary sites.
    J Pharm Sci. 1974 Sep;63(9):1423-7 PMID: 4427265
  71. The determination of azapropazone in blood plasma.
    Curr Med Res Opin. 1976;4(1):35-43 PMID: 1261300
  72. Prednisolone clearance at steady state in dogs.
    J Pharmacol Exp Ther. 1980 Nov;215(2):287-91 PMID: 7441495
  73. Phenytoin--valproic acid interaction in rhesus monkey.
    Epilepsia. 1981 Feb;22(1):19-25 PMID: 6781887
  74. The quinidine-digoxin interaction: what do we know about it?
    N Engl J Med. 1979 Oct 4;301(14):779-81 PMID: 481483
  75. Absence of effect of heparin on the binding of prazosin and phenytoin to plasma proteins.
    Biochem Pharmacol. 1980 Dec;29(24):3337-40 PMID: 7213407
  76. Effect of oral disopyramide on serum digoxin levels. A prospective study.
    Am Heart J. 1980 Dec;100(6 Pt 1):934-5 PMID: 7446396
  77. Lack of interaction between ibuprofen and warfarin.
    Curr Ther Res Clin Exp. 1975 Dec;18(6):862-71 PMID: 813951
  78. Digoxin-quinidine interaction.
    N Engl J Med. 1979 Sep 27;301(13):727-8 PMID: 481475
  79. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.
    N Engl J Med. 1978 Dec 28;299(26):1435-9 PMID: 82206
  80. Computer analysis of drug-protein binding data.
    Ann N Y Acad Sci. 1973 Nov 26;226:69-81 PMID: 4520404
  81. Digoxin-quinidine interaction Pharmacokinetic evaluation.
    N Engl J Med. 1979 May 31;300(22):1238-41 PMID: 431681
  82. Drug-albumin binding.
    Biochem Soc Trans. 1975;3(5):635-40 PMID: 1193256
  83. Protein interactions of sulfonylurea compounds.
    Diabetes. 1962;11(Suppl):18-25 PMID: 14001333
  84. Interactions of valproic acid with phenytoin.
    Neurology. 1980 Nov;30(11):1233-6 PMID: 6775245
  85. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.
    J Clin Invest. 1974 Jun;53(6):1607-17 PMID: 4830225
  86. Plasma and tissue protein binding of drugs in pharmacokinetics.
    Drug Metab Rev. 1976;5(1):43-140 PMID: 829788
  87. [Determination of the binding of sulfonamides to serum proteins with the ultracentrifuge].
    Arzneimittelforschung. 1961 Dec;11:1133-7 PMID: 13874470
  88. Binding of drugs to serum albumin (first of two parts).
    N Engl J Med. 1976 Feb 5;294(6):311-6 PMID: 1107839
  89. Decreased plasma protein binding of phenytoin in patients on valproic acid.
    Br J Clin Pharmacol. 1979 Dec;8(6):547-52 PMID: 391256
  90. Drug distribution as a function of binding competition. Experiments with the distribution dialysis technique.
    J Pharm Pharmacol. 1980 Oct;32(10):669-74 PMID: 6107337
  91. Measurement of protein-binding phenomena by gel filtration.
    Biochim Biophys Acta. 1962 Oct 8;63:530-2 PMID: 13955687
Article Info
Journal
Drugs
Abbr.
Drugs
ISSN
0012-6667
Published
1983-05-00
Pages
495-513
Language
English
Region
New Zealand
NLM ID
7600076
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com